KMS Medisurgi (BOM:540468) 3-Year EBITDA Growth Rate: -2.60% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540468 KMS Medisurgi Ltd BOM:540468
79 GF Score
Price ₹132.80
GF Value ₹111.52
! 8 Warning Signs
View Full Analysis

What is KMS Medisurgi 3-Year EBITDA Growth Rate?

KMS Medisurgi BOM:540468 79 3-Year EBITDA Growth Rate is -2.60% as of Mar. 2026. GuruFocus rates BOM:540468 with a GF Score™ of 79/100 and a GF Value™ of ₹111.52. The stock has 8 warning signs investors should review.

KMS Medisurgi's EBITDA per Share for the six months ended in Mar. 2026 was ₹1.03.

During the past 12 months, KMS Medisurgi's average EBITDA Per Share Growth Rate was -5.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -2.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 11.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of KMS Medisurgi was 95.90% per year. The lowest was -34.40% per year. And the median was 7.90% per year.


KMS Medisurgi  (BOM:540468) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


KMS Medisurgi 3-Year EBITDA Growth Rate Related Terms


BOM:540468 vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison

For the Medical Instruments & Supplies subindustry, KMS Medisurgi's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KMS Medisurgi 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KMS Medisurgi's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where KMS Medisurgi's 3-Year EBITDA Growth Rate falls into.


BOM:540468
79GF Score
KMS Medisurgi Ltd BOM:540468
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KMS Medisurgi 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -2.60% mean?
KMS Medisurgi (BOM:540468) has a 3-Year EBITDA Growth Rate of -2.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for KMS Medisurgi and its competitors.
Is KMS Medisurgi's 3-Year EBITDA Growth Rate too high?
KMS Medisurgi's current 3-Year EBITDA Growth Rate is -2.60%. Overall, KMS Medisurgi has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does KMS Medisurgi's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
KMS Medisurgi's 3-Year EBITDA Growth Rate of -2.60% can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for KMS Medisurgi and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KMS Medisurgi's current 3-Year EBITDA Growth Rate is -2.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KMS Medisurgi stock overvalued right now?
KMS Medisurgi (BOM:540468) has a current 3-Year EBITDA Growth Rate of -2.60%. The stock's GF Value™ is ₹111.52, compared to a current price of ₹132.80 — trading 19.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -2.60%. KMS Medisurgi's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For KMS Medisurgi (BOM:540468), the current 3-Year EBITDA Growth Rate is -2.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KMS Medisurgi (BOM:540468) Overvalued in 2026?

Based on GuruFocus' analysis, KMS Medisurgi stock appears to be overvalued. The current stock price of ₹132.80 is trading 19.1% above its estimated GF Value™ of ₹111.52.

Key valuation signals for BOM:540468:

  • 3-Year EBITDA Growth Rate: -2.60%
  • GF Value™: ₹111.52 vs. price of ₹132.80 (19.1% above fair value)
  • GF Score™: 79/100 with 8 warning signs

No single metric tells the full story. See the BOM:540468 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


KMS Medisurgi Business Description

Address Princess Street, Ground Floor, 297-301, May Building, Marine Lines (East, Mumbai, MH, IND, 400002
KMS Medisurgi Ltd manufactures surgical tapes and dressings for hospitals, institutions, trade associations, exporters, and importers. The company manufactures and undertakes job work of various substartes like non-woven fabrics, PU films, cotton fabrics, and taffeta silk fabrics with adhesive. The company's international presence includes Vietnam, Dubai, Europe, Australia, Cambodia, India, Africa, Philippines, Russia, Pakistan, Bangladesh, and the USA. The company derives revenue from the sale of goods.
79GF Score

Get the complete analysis for BOM:540468

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹132.80
Price
₹111.52
GF Value